SAB Biotherapeutics Inc
SABS
Get informed when a big investor buys or sells
+ FollowMarket Cap$258.4M
Close$
$0.07
97.3% downside
Current Fair Value
97.3% downsideOvervalued by 97.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $258.40 Million |
|---|---|
| Enterprise Value | $255.27 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.22 |
| Beta | 0.58 |
| Outstanding Shares | 79,753,100 |
Return
| Return on Equity | -5.95% |
|---|---|
| Return on Assets | -5.36% |
| Return on Invested Capital | -59.32% |
Valuation & Multiples
| P/E Ratio | 0.8 |
|---|---|
| PEG | 0.65 |
| Price to Sales | - |
| Price to Book Ratio | 1.4 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.9 |
| Enterprise Value to Net Income | -20 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$125,000
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$125,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 138.96% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.39%▼ 85.51% |
|---|---|
| Total Invested | $975,463▼ 99.63% |
| Investors Holding | 1▼ 91.00% |
ESG Score
No data
About SAB Biotherapeutics Inc
81 employeessab biotherapeutics is a clinical-stage biopharmaceutical development company using its novel immunotherapy platform to produce life-saving therapies.